Company news

Phio Pharmaceuticals Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

April 9, 2025

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

April 3, 2025

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

March 31, 2025

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

March 10, 2025

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

March 5, 2025

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

February 20, 2025

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

January 21, 2025

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 20, 2025

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 15, 2025

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 14, 2025

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 13, 2025

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

January 12, 2025

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

January 1, 2025

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 22, 2024

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

December 18, 2024

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 18, 2024

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

December 11, 2024

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

December 9, 2024

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

November 18, 2024

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 13, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 6, 2024

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

October 17, 2024

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

October 17, 2024

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

October 15, 2024

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

October 6, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference

September 30, 2024

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

September 24, 2024

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

September 15, 2024

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 8, 2024

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

August 5, 2024

Phio Pharmaceuticals Announces New Chief Financial Officer

July 31, 2024

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

July 11, 2024

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

July 7, 2024

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

July 4, 2024

Phio Pharmaceuticals Announces Reverse Stock Split

July 1, 2024

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

June 17, 2024

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 27, 2024

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 22, 2024

Phio Pharmaceuticals Secures New Investor

May 16, 2024

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

May 15, 2024

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

May 14, 2024

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

May 8, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

April 29, 2024

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

April 21, 2024

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

April 15, 2024

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

April 10, 2024

← Newer news releases · Older news releases →

Decks

The 5 newest of 9 decks. Every deck is listed under its year.